Home  »  Business   »  BioXcel Therapeutics Inc. (BTAI) Is A Good Stock T...

BioXcel Therapeutics Inc. (BTAI) Is A Good Stock To Invest In

BioXcel Therapeutics Inc. (NASDAQ:BTAI) concluded the trading at $15.51 on Wednesday, November 23 with a rise of 5.37% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $14.72 and 5Y monthly beta was reading 1.26. Considering stock’s 52-week price range provides that BTAI hit a high price of $24.72 and saw its price falling to a low level of $8.80 during that period. Over a period of past 1-month, stock came adding 26.92% in its value.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


With its current market valuation of $444.98 million, BioXcel Therapeutics Inc. is set to declare its quarterly results on Nov 10, 2022. Analysts are in estimates of -$1.35 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$5.1 for 2022 with estimates of that growing to -$4.96 in next year. These estimates are suggesting current year growth of -25.90% for EPS and 2.70% growth next year.

Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $1.09 million.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review BTAI stock’s current outlook then short term indicators are assigning it an average of Hold, while medium term indicators are categorizing the stock at an average of 50% Sell. Long term indicators are suggesting an average of 50% Buy for it.

Digging deeper we become aware of the PEG ratio of the BTAI stock which is currently positioned at 0. It further provides that stock’s current price level is 14.71% away from its 20-day simple moving average and is 25.64% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 63.24 while volatility remained at 6.63% over the past week which changes to 8.81% when measuring it over the past month. Beta is valued at 1.23, while measure of average true range or ATR is currently at 1.12.

Having a second look at BioXcel Therapeutics Inc. (NASDAQ:BTAI) provides that stock’s average daily trading volume for 3 months was 216.13K, while it jumped to 0.32 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 28.02 million.

The percentage of outstanding shares held by the insiders is 32.23% while it is 47.90% for the institutional holders. The figures also indicate that as of Oct 13, 2022, number of stock’s short shares was 2.64 million which implies a short ratio of 12.82. This shows down a 9.44% of Short Interest in company’s outstanding shares on the day. In October the standing of shares short improved as it was 2.86 million in the previous month. Subtraction of -23.71% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.

Leave a Comment

Your email address will not be published. Required fields are marked *